Earnings Summary

Cytomx Therapeutics Inc’s revenue jumped 2712.58% since last year same period to $26.61Mn in the Q4 2023. On a quarterly growth basis, Cytomx Therapeutics Inc has generated 0.85% jump in its revenue since last 3-months.

Cytomx Therapeutics Inc’s net profit jumped 103.15% since last year same period to $0.84Mn in the Q4 2023. On a quarterly growth basis, Cytomx Therapeutics Inc has generated -72.03% fall in its net profits since last 3-months.

Cytomx Therapeutics Inc’s net profit margin jumped 100.11% since last year same period to 3.15% in the Q4 2023. On a quarterly growth basis, Cytomx Therapeutics Inc has generated -72.26% fall in its net profit margins since last 3-months.

Cytomx Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.05 - a -66.67% fall from last quarter’s estimates.

Cytomx Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.05.

Cytomx Therapeutics Inc’s earning per share (EPS) jumped 102.33% since last year same period to 0.01 in the Q4 2023. This indicates that the Cytomx Therapeutics Inc has generated 102.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cytomx Therapeutics Inc’s return on assets (ROA) stands at -0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cytomx Therapeutics Inc’s return on equity (ROE) stands at -54.75.